314 unknown. 314 Phase 2, 83 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 314 | Unknown 314 |
| Phase 1 | 83 | Unknown 83 |
| Phase 3 | 11 | Unknown 11 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-amyloid as a Marker for GBM Bioimaging Amyvid, Intravenous Solution - Glioblastoma | Phase 2 | Unknown | Universidad Central del Caribe | 3 | 2024-07-01 | 2023-12-21 |
| Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. ZG005, Etoposide, Cisplatin - Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 93 | 2024-05-30 | 2024-06-14 |
| FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery FG001 prior to surgery - Low-grade Glioma, Meningioma | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 40 | 2024-05-01 | 2024-11-12 |
| TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ) - Glioblastoma Multiforme | Phase 2 | Unknown | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | 30 | 2024-04-30 | 2024-08-09 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. Sodium Chloride Granules, Water - Melanoma (Skin) | Phase 2 | Unknown | Rafik Batroussy | 20 | 2023-08-01 | 2023-05-11 |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies ILB-2109, Toripalimab - Head and Neck Cancer, Cervical Cancer | Phase 1 / Phase 2 | Unknown | Innolake Biopharm | 200 | 2023-07-25 | 2024-05-21 |
| Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors Lutetium[177Lu] Oxodotreotide Injection - Neuroendocrine Tumors | Phase 2 | Unknown | Peking University | 40 | 2023-06-05 | 2023-06-08 |
| B7-H3 CAR-T for Recurrent or Refractory Glioblastoma Temozolomide, B7-H3 CAR-T - Recurrent Glioblastoma, Refractory Glioblastoma | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-06-01 | 2022-12-28 |
| Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients Sintilimab plus Bevacizumab and Temozolomide - Recurrent Glioblastoma | Phase 2 | Unknown | Zhujiang Hospital | 30 | 2023-05-01 | 2024-06-05 |
| The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma Toripalimab combined with Temozolomide - Melanoma Stage III | Phase 2 | Unknown | Yong Chen | 20 | 2023-05-01 | 2023-04-25 |
| A Study of TY-1091 in Patients With Advanced Solid Tumors TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | TYK Medicines, Inc | 248 | 2023-04-24 | 2024-01-30 |
| Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma QLF31907 - Melanoma, Urothelial Carcinoma | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 66 | 2023-04-24 | 2023-05-26 |
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment Penpulimab - Pheochromocytoma, Metastatic, Pheochromocytoma Malignant | Phase 2 | Unknown | Peking Union Medical College Hospital | 5 | 2023-04-01 | 2023-06-02 |
| A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL Temozolomide - Pheochromocytoma, Paraganglioma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2023-04-01 | 2023-06-01 |
| Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors Al18F-NOTA-LM3, 68Ga-DOTATATE, 68Ga-NODAGA-LM3 - Neuroendocrine Tumors | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 80 | 2023-03-23 | 2025-04-02 |
| KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma KD6001, Toripalimab - Melanoma | Phase 1 / Phase 2 | Unknown | Shanghai Kanda Biotechnology Co., Ltd. | 84 | 2023-03-22 | 2023-04-27 |
| L19IL2/L19TNF in Skin Cancer Patients L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 2 | Unknown | Philogen S.p.A. | 70 | 2023-03-09 | 2023-10-06 |
| Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel - Malignant Melanoma, Liver Metastases | Phase 2 | Unknown | Fujian Cancer Hospital | 30 | 2023-02-01 | 2023-02-08 |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms 18F-FDG, 64Cu-Dotatate - GEP-NET, Neuroendocrine Tumors | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 200 | 2023-01-17 | 2023-11-22 |
Showing 20 of 314. Sign in to see all of them.
Melanoma (120) · Glioblastoma (75) · Glioma (34) · Neuroendocrine Tumors (27) · Brain Neoplasms (20) · Neuroblastoma (20) · Neoplasm Metastasis (18) · Carcinoma, Neuroendocrine (17) · Carcinoma, Non-Small-Cell Lung (14) · Central Nervous System Neoplasms (14) · Gliosarcoma (14) · Astrocytoma (13) · Neoplasms (13) · Uveal Melanoma (11) · Carcinoma, Renal Cell (9)
Neoplasms by Histologic Type (314) · Neoplasms, Germ Cell and Embryonal (313) · Neoplasms, Nerve Tissue (313) · Neoplasms (301) · Neoplasms, Glandular and Epithelial (177) · Neoplasms by Site (174) · Neuroendocrine Tumors (153) · Neoplasms, Neuroepithelial (136) · Nevi and Melanomas (127) · Skin Diseases (122) · Skin and Connective Tissue Diseases (122) · Skin Neoplasms (120) · Glioma (80) · Astrocytoma (68)
Temozolomide (46) · Radiotherapy (20) · pembrolizumab (17) · Carboplatin (16) · Nivolumab (16) · Bevacizumab (13) · Cisplatin (12) · Cyclophosphamide (9) · Etoposide (9) · Ipilimumab (9) · anlotinib (8) · Drug Therapy (7) · Everolimus (7) · apatinib (7) · camrelizumab (7)
Peking Union Medical College Hospital (10) · Peking University Cancer Hospital & Institute (10) · Assistance Publique - Hôpitaux de Paris (7) · Peking University (7) · Children's Cancer and Leukaemia Group (6) · Huashan Hospital (6) · Copenhagen University Hospital, Rigshospitalet (5) · Gustave Roussy, Cancer Campus, Grand Paris (4) · San Diego Pacific Oncology & Hematology Associates (4) · The Netherlands Cancer Institute (4) · California Pacific Medical Center Research Institute (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Fudan University (3) · Kentuckiana Cancer Institute (3) · Leiden University Medical Center (3)
China (89) · United States (74) · France (25) · Italy (21) · Germany (20) · Netherlands (13) · United Kingdom (12) · Australia (10) · Austria (10) · Belgium (10) · Spain (10) · Canada (9) · Israel (9) · South Korea (9) · Switzerland (9)
Edward F. McClay, MD (4) · Jun Guo, MD (4) · Anli Tong (3) · Amy E. Bock (2) · Andreas Kjaer, MD (2) · Chunmei Bai, M.D. (2) · David A. Walker (2) · Edward A Neuwelt (2) · Enmin Wang, MD (2) · Gene David Resnick, MD (2) · Guenther Stockhammer, MD, Prof. (2) · Jean Marie Michon, MD (2) · Jeffrey Raizer, MD (2) · John Fiveash, MD (2) · Kevin B Kim, MD (2)
PMID 33990415, PMID 36648215, PMID 10655437, PMID 11937316, PMID 12177103, PMID 12434281, PMID 12902325, PMID 14506149, PMID 15588232, PMID 15809479, PMID 16011702, PMID 16078267, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 16801334, PMID 16877732, PMID 17544337, PMID 17647306, PMID 17909941, PMID 18217208, PMID 18577561, PMID 18810319, PMID 18990510, PMID 19147777, PMID 19957326, PMID 19985059, PMID 20150268, PMID 20406835, PMID 20694800, PMID 20708924, PMID 20921456, PMID 20974795, PMID 21087935, PMID 21171927, PMID 21292687, PMID 21297126, PMID 21297433, PMID 21306237, PMID 21327862, PMID 22132908, PMID 22331797, PMID 22747087, PMID 22747092, PMID 23043252, PMID 23092726, PMID 23536435, PMID 23670576, PMID 23715562
2016 (3), 2019 (3), 2009 (2), 2014 (2), 2015 (2), 2018 (2), 2004 (1), 2017 (1), M01RR000096 (1), P30CA022453 (1), P30CA060553 (1), R01NS044687 (1)